132 results on '"Odening, K"'
Search Results
2. SGK1 inhibition normalizes action potential duration in transgenic LQT2 rabbits but not in LQT1, suggesting a novel gene-specific therapeutic approach in long QT syndrome
- Author
-
Barbieri, M, primary, Lourdaour, J, additional, Alerni, N, additional, Giammarino, L, additional, Nimani, S, additional, Matas, L, additional, Horvath, A, additional, and Odening, K E, additional
- Published
- 2024
- Full Text
- View/download PDF
3. In vivo KCNH2-suppression-replacement gene therapy attenuates the pathogenic phenotype in transgenic rabbits with short QT syndrome type 1
- Author
-
Nimani, S, primary, Bains, S, additional, Alerni, N, additional, Giammarino, L, additional, Louradour, J, additional, Horvath, A, additional, Beslac, O, additional, Tester, D J, additional, Christoforou, N, additional, Brunner, M, additional, Casoni, D, additional, Haeberlin, A, additional, Brooks, G, additional, Ackerman, M J, additional, and Odening, K E, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Interplay of electrical and mechanical properties in transgenic rabbit models of long-QT and short-QT syndrome
- Author
-
Alerni, N, primary, Nimani, S, additional, Hornyik, T, additional, Barbieri, M, additional, Louradour, J, additional, Giammarino, L, additional, Matas, L, additional, Perez-Feliz, S, additional, Zehender, M, additional, Brunner, M, additional, and Odening, K, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Temporal variability of electromechanical-window negativity in patients with inherited long-QT syndrome or drug-induced QT prolongation: relation to torsades de pointes
- Author
-
Deissler, P, primary, Berkovitch, A, additional, Rahm, A K, additional, Sikking, M, additional, Moersdorf, M, additional, Sohns, C, additional, Rieder, M, additional, Nimani, S, additional, Odening, K E, additional, Sabbag, A, additional, Volders, P G A, additional, and Ter Bekke, R M A, additional
- Published
- 2024
- Full Text
- View/download PDF
6. In vivo KCNQ1-suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome
- Author
-
Giammarino, L, primary, Nimani, S, additional, Bains, S, additional, Alerni, N, additional, Tester, D J, additional, Christoforou, N, additional, Louradour, J, additional, Jurgensen, J, additional, Barry, M A, additional, Koren, G, additional, Zehender, M, additional, Brunner, M, additional, Brooks, G, additional, Ackerman, M J, additional, and Odening, K E, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Electromechanical heterogeneity in the heart: A key to long QT syndrome?
- Author
-
Dressler, F. F., Brado, J., and Odening, K. E.
- Published
- 2018
- Full Text
- View/download PDF
8. Avoiding sports-related sudden cardiac death in children with congenital channelopathy: Recommendations for sports activities
- Author
-
Lang, C. N., Steinfurt, J., and Odening, K. E.
- Published
- 2017
- Full Text
- View/download PDF
9. Metabolic treatment of an electrical disease? Beneficial APD/QT prolongation by L-Carnitine in transgenic SQT1 rabbit models
- Author
-
Hornyik, T, primary, Bodi, I, additional, Michaelides, K, additional, Mettke, L, additional, Perez-Feliz, S, additional, El-Battrawy, I, additional, Brunner, M, additional, Bode, C, additional, and Odening, K, additional
- Published
- 2021
- Full Text
- View/download PDF
10. Differences in extent of mechano-induced QT-changes in SQTS, WT and LQTS rabbit models
- Author
-
Nimani, S, primary, Hornyik, T, additional, Alerni, N, additional, Lewetag, R, additional, Giammarino, L, additional, Perez-Feliz, S, additional, Matas, L, additional, Moss, K R, additional, Zehender, M, additional, Brunner, M, additional, Seemann, G, additional, and Odening, K E, additional
- Published
- 2021
- Full Text
- View/download PDF
11. On the emerging role of rabbit as human disease model and the instrumental role of novel transgenic tools
- Author
-
Duranthon, V., Beaujean, N., Brunner, M., Odening, K. E., Santos, A. Navarrete, Kacskovics, I., Hiripi, L., Weinstein, E. J., and Bosze, Z.
- Published
- 2012
- Full Text
- View/download PDF
12. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells
- Author
-
Odening, K. E., Li, W., Rutz, R., Laufs, S., Fruehauf, S., Fishelson, Z., and Kirschfink, M.
- Published
- 2009
13. P604Docosahexaenoic acid acts as QT-shortening agent with genotype-tspecific beneficial effects in transgenic LQT1, LQT2, LQT5 and LQT2-5 rabbit models
- Author
-
Castiglione, A, primary, Hornyik, T, additional, Franke, G, additional, Perez-Feliz, S, additional, Bosze, Z, additional, Koren, G, additional, Varro, A, additional, Zehender, M, additional, Brunner, M, additional, Bode, C, additional, Baczko, I, additional, and Odening, K E, additional
- Published
- 2018
- Full Text
- View/download PDF
14. 5922Oxytocin has harmful cardiac repolarization prolonging effects - Particularly in context of drug-induced LQTS
- Author
-
Kreifels, P, primary, Franke, G, additional, Perez-Feliz, S, additional, Bodi, I, additional, Castiglione, A, additional, Ziupa, D, additional, Bode, C, additional, and Odening, K E, additional
- Published
- 2018
- Full Text
- View/download PDF
15. Electromechanical heterogeneity in the heart
- Author
-
Dressler, F. F., primary, Brado, J., additional, and Odening, K. E., additional
- Published
- 2017
- Full Text
- View/download PDF
16. Possible mechanisms for sensorineural hearing loss and deafness in patients with propionic acidemia
- Author
-
Grünert, S. C., primary, Bodi, I., additional, and Odening, K. E., additional
- Published
- 2017
- Full Text
- View/download PDF
17. THE LIFE CYCLE OF CODONOCEPHALUS URNIGER (RUDOLPHI) (TREMATODA)
- Author
-
ODENING, K., primary
- Published
- 1966
- Full Text
- View/download PDF
18. EXPERIMENTAL RESULTS ON FINAL HOST SPECIFICITY OF TWO SPECIES OF NEODIPLOSTOMUM (TREMATODA: STRIGEIDA)
- Author
-
ODENING, K., primary
- Published
- 1966
- Full Text
- View/download PDF
19. THE LIFE CYCLE OF STRIGEA FALCONIS SZIDAT (TREMATODA) IN CENTRAL EUROPE
- Author
-
ODENING, K., primary
- Published
- 1966
- Full Text
- View/download PDF
20. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells
- Author
-
Odening, K E, primary, Li, W, additional, Rutz, R, additional, Laufs, S, additional, Fruehauf, S, additional, Fishelson, Z, additional, and Kirschfink, M, additional
- Published
- 2008
- Full Text
- View/download PDF
21. Fin fold formula in the genus Echinostoma (Trematoda: Echinostomatidae)
- Author
-
Kanev, I., Busta, J., Vassilev, I., Fried, B., Odening, K., Eisenhut, U., Ostrowski de Nuñez, M., and Manga-González, M. Yolanda
- Subjects
Tail ,Echinostoma ,Fin fold ,Formula - Abstract
Trabajo presentado al VIIth International Congress of Parasitology (París, 20 al 24 de agosto de 1990)., Echinostome cercariae with 31, 37, 43, 47 and 51 collar spines obtained from experimentally and naturally infected planorbid, lymnaeid, physid and viviparid snails, collected in 25 different geographical regions in Europe, Asia, Africa, North and South America, including Germany the type locality for E.revolutum, were examined with respect to the number and arrangement of fin folds on the tail surface...
- Published
- 1990
22. Scanning electron microscopic identification of Sarcocystis gracilis from roe deer and cattle
- Author
-
Stolte, M., primary, Bockhardt, I., additional, and Odening, K., additional
- Published
- 1998
- Full Text
- View/download PDF
23. Sarcocystis kirmsei in the brain of a hill mynah (Gracula religiosa)
- Author
-
Jakob, W., primary, Stolte, M., additional, Odening, K., additional, and Bockhardt, I., additional
- Published
- 1998
- Full Text
- View/download PDF
24. On the diagnostics of Sarcocystis in cattle: sarcocysts of a species unusual for Bos taurus in a dwarf zebu
- Author
-
Odening, K., primary, Stolte, M., additional, and Bockhardt, I., additional
- Published
- 1996
- Full Text
- View/download PDF
25. A comparative scanning electron microscopic study of the cyst wall in 11Sarcocystisspecies of mammals
- Author
-
Srolte, Manuela, primary, Bockhardt, Ingrid, additional, and Odening, K., additional
- Published
- 1996
- Full Text
- View/download PDF
26. Three New Sarcocystis Species, Sarcocystis giraffae, S. klaseriensis, and S. camelopardalis (Protozoa: Sarcocystidae) from the Giraffe (Giraffa camelopardalis) in South Africa
- Author
-
Bockhardt I, Odening K, S. Quandt, R G Bengis, and M. Stolte
- Subjects
Giraffidae ,biology ,Ground substance ,Anatomy ,biology.organism_classification ,law.invention ,law ,Sarcocystidae ,Ultrastructure ,Sarcocystis ,media_common.cataloged_instance ,Parasite hosting ,Parasitology ,Electron microscope ,Ecology, Evolution, Behavior and Systematics ,Giraffa camelopardalis ,media_common - Abstract
Three new Sarcocystis species recovered from muscle fibers of the skeletal musculature of a giraffe in South Africa are described based on light and electron microscopy. Sarcocystis giraffae n. sp. formed slim macrocysts with a parasite-induced connective tissue encapsulation of the host muscle fiber in which the plasma membrane of the latter remained unaltered. The sarcocyst wall represented a new ultrastructural type that is characterized by fingerlike villar protrusions with a hairlike projection at the tip, containing microtubules penetrating the ground substance. Sarcocystis klaseriensis n. sp. formed small filiform microcysts with kinked finger-shaped villar protrusions of the wall, containing scattered microtubules or filaments, and represented another new ultrastructural type. Sarcocystis camelopardalis n. sp. formed small filiform microcysts with straplike villar protrusions of the wall, containing chainlike osmiophilic structures, and represented again a new ultrastructural type.
- Published
- 1998
27. Sarcocysts (Sarcocystis sp.: Sporozoa) in the European badger, Meles meles
- Author
-
Odening, K., primary, Stolte, M., additional, Walter, G., additional, Bockhardt, I., additional, and Jakob, W., additional
- Published
- 1994
- Full Text
- View/download PDF
28. The european badger (carnivora: mustelidae) as intermediate host of further threeSarcocystisspecies (sporozoa)
- Author
-
Odening, K., primary, Stolte, M., additional, Walters, G., additional, and Bockhardt, I., additional
- Published
- 1994
- Full Text
- View/download PDF
29. Sarcocystis dubeyella n. sp. and Sarcocystis phacochoeri n. sp. (Protozoa: Sarcocystidae) from the Warthog (Phacochoerus aethiopicus) in South Africa.
- Author
-
Stolte, M., Odening, K., Quandt, S., Bengis, R. G., and Bockhardt, I.
- Published
- 1998
30. Scanning electron microscopic identification of <e1>Sarcocystis gracilis</e1> from roe deer and cattle
- Author
-
*, M. Stolte, , Bockhardt, I., and Odening, K.
- Abstract
Sarcocysts morphologically not distinguishable from
Sarcocystis gracilis of roe deer (Capreolus capreolus , Cervidae) were found in the skeletal musculature of dwarf zebu and humpless cattle (Bos taurus , Bovidae). We contribute to the identification of this species by means of scanning electron microscopy. Special attention is paid to the species-specific cyst wall structure. Our findings confirm previous descriptions by light and transmission electron microscopy and support the peculiarity and uniqueness of the cyst wall type gracilis.- Published
- 1998
31. Possible mechanisms for sensorineural hearing loss and deafness in patients with propionic acidemia
- Author
-
Grünert, S. C., Bodi, I., and Odening, K. E.
- Subjects
Medicine(all) ,congenital, hereditary, and neonatal diseases and abnormalities ,otorhinolaryngologic diseases ,Genetics(clinical) ,Pharmacology (medical) - Full Text
- View/download PDF
32. A new Amphistome cercaria fromLymnaea truncatulain Europe
- Author
-
Odening, K., primary and Samnaliev, P., additional
- Published
- 1987
- Full Text
- View/download PDF
33. A propos de la validité d’Ichthyocotylurus variegatus (Creplin, 1825) et de la position spécifique de Tetracotyle ovata (v. Linstow, 1877) (Trematoda : Strigeidae)
- Author
-
Odening, K., primary
- Published
- 1979
- Full Text
- View/download PDF
34. Cyst Wall Ultrastructure of Two Sarcocystis spp. from European Mouflon (Ovis ammon musimon) in Germany Compared with Domestic Sheep
- Author
-
Odening, K., Stolte, M., Walter, G., and Bockhardt, I.
- Published
- 1995
- Full Text
- View/download PDF
35. New trends in parasitic infections of cultured freshwater fish
- Author
-
Odening, K.
- Published
- 1989
- Full Text
- View/download PDF
36. Gene- and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2
- Author
-
Giannetti, Federica, Barbieri, Miriam, Shiti, Assad, Casini, Simona, Sager, Philip T, Das, Saumya, Pradhananga, Sabindra, Srinivasan, Dinesh, Nimani, Saranda, Alerni, Nicolò, Louradour, Julien, Mura, Manuela, Gnecchi, Massimiliano, Brink, Paul, Zehender, Manfred, Koren, Gideon, Zaza, Antonio, Crotti, Lia, Wilde, Arthur A M, Schwartz, Peter J, Remme, Carol Ann, Gepstein, Lior, Sala, Luca, Odening, Katja E, Giannetti, F, Barbieri, M, Shiti, A, Casini, S, Sager, P, Das, S, Pradhananga, S, Srinivasan, D, Nimani, S, Alerni, N, Louradour, J, Mura, M, Gnecchi, M, Brink, P, Zehender, M, Koren, G, Zaza, A, Crotti, L, Wilde, A, Schwartz, P, Remme, C, Gepstein, L, Sala, L, and Odening, K
- Subjects
Cellular electrophysiology ,Physiology (medical) ,LQTS ,Animal model ,610 Medicine & health ,610 Medizin und Gesundheit ,Cardiology and Cardiovascular Medicine ,Genotype-specific therapy ,hiPSC ,Mechanism-based therapy - Abstract
Aims Current long QT syndrome (LQTS) therapy, largely based on beta-blockade, does not prevent arrhythmias in all patients; therefore, novel therapies are warranted. Pharmacological inhibition of the serum/glucocorticoid-regulated kinase 1 (SGK1-Inh) has been shown to shorten action potential duration (APD) in LQTS type 3. We aimed to investigate whether SGK1-Inh could similarly shorten APD in LQTS types 1 and 2. Methods and results Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and hiPSC-cardiac cell sheets (CCS) were obtained from LQT1 and LQT2 patients; CMs were isolated from transgenic LQT1, LQT2, and wild-type (WT) rabbits. Serum/glucocorticoid-regulated kinase 1 inhibition effects (300 nM–10 µM) on field potential durations (FPD) were investigated in hiPSC-CMs with multielectrode arrays; optical mapping was performed in LQT2 CCS. Whole-cell and perforated patch clamp recordings were performed in isolated LQT1, LQT2, and WT rabbit CMs to investigate SGK1-Inh (3 µM) effects on APD. In all LQT2 models across different species (hiPSC-CMs, hiPSC-CCS, and rabbit CMs) and independent of the disease-causing variant (KCNH2-p.A561V/p.A614V/p.G628S/IVS9-28A/G), SGK1-Inh dose-dependently shortened FPD/APD at 0.3–10 µM (by 20–32%/25–30%/44–45%). Importantly, in LQT2 rabbit CMs, 3 µM SGK1-Inh normalized APD to its WT value. A significant FPD shortening was observed in KCNQ1-p.R594Q hiPSC-CMs at 1/3/10 µM (by 19/26/35%) and in KCNQ1-p.A341V hiPSC-CMs at 10 µM (by 29%). No SGK1-Inh-induced FPD/APD shortening effect was observed in LQT1 KCNQ1-p.A341V hiPSC-CMs or KCNQ1-p.Y315S rabbit CMs at 0.3–3 µM. Conclusion A robust SGK1-Inh-induced APD shortening was observed across different LQT2 models, species, and genetic variants but less consistently in LQT1 models. This suggests a genotype- and variant-specific beneficial effect of this novel therapeutic approach in LQTS.
- Published
- 2023
37. ESC working group on cardiac cellular electrophysiology position paper: relevance, opportunities, and limitations of experimental models for cardiac electrophysiology research
- Author
-
Dierk Thomas, Milan Stengl, Dobromir Dobrev, Matteo E. Mangoni, Jordi Heijman, Carol Ann Remme, Larissa Fabritz, Katja E. Odening, Godfrey L. Smith, Cristina E. Molina, Leonardo Sacconi, A.M. Gomez, Antonio Zaza, Frank R. Heinzel, Cardiologie, RS: Carim - H01 Clinical atrial fibrillation, RS: Carim - H04 Arrhythmogenesis and cardiogenetics, Cardiology, ACS - Heart failure & arrhythmias, APH - Methodology, University of Bern, Odening, K, Gomez, A, Dobrev, D, Fabritz, L, Heinzel, F, Mangoni, M, Molina, C, Sacconi, L, Smith, G, Stengl, M, Thomas, D, Zaza, A, Remme, C, and Heijman, J
- Subjects
0301 basic medicine ,TORSADE-DE-POINTES ,Cardiac electrophysiology ,Medizin ,Cardiomyopathy ,Arrhythmias ,030204 cardiovascular system & hematology ,0302 clinical medicine ,BIO/09 - FISIOLOGIA ,Mechanisms ,Position paper ,Induced pluripotent stem cell ,LEFT-VENTRICULAR WALL ,SINOATRIAL NODE ,Atrial fibrillation ,Animal models ,3. Good health ,PRESERVED EJECTION FRACTION ,Ion channels ,cardiovascular system ,HEART-FAILURE ,Mechanism ,Ion channel ,Electrophysiologic Techniques, Cardiac ,Cardiology and Cardiovascular Medicine ,Experimental models ,PLURIPOTENT STEM-CELLS ,Arrhythmia ,Myocarditis ,Cellular electrophysiology ,LONG-QT SYNDROME ,03 medical and health sciences ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Physiology (medical) ,SINUS NODE DYSFUNCTION ,medicine ,Animals ,Humans ,Animal model ,Experimental model ,business.industry ,TRANSGENIC RABBIT MODEL ,Cardiac arrhythmia ,Models, Theoretical ,medicine.disease ,Electrophysiological Phenomena ,030104 developmental biology ,Heart failure ,ATRIAL-FIBRILLATION ,business ,Neuroscience - Abstract
Cardiac arrhythmias are a major cause of death and disability. A large number of experimental cell and animal models have been developed to study arrhythmogenic diseases. These models have provided important insights into the underlying arrhythmia mechanisms and translational options for their therapeutic management. This position paper from the ESC Working Group on Cardiac Cellular Electrophysiology provides an overview of (i) currently available in vitro, ex vivo, and in vivo electrophysiological research methodologies, (ii) the most commonly used experimental (cellular and animal) models for cardiac arrhythmias including relevant species differences, (iii) the use of human cardiac tissue, induced pluripotent stem cell (hiPSC)-derived and in silico models to study cardiac arrhythmias, and (iv) the availability, relevance, limitations, and opportunities of these cellular and animal models to recapitulate specific acquired and inherited arrhythmogenic diseases, including atrial fibrillation, heart failure, cardiomyopathy, myocarditis, sinus node, and conduction disorders and channelopathies. By promoting a better understanding of these models and their limitations, this position paper aims to improve the quality of basic research in cardiac electrophysiology, with the ultimate goal to facilitate the clinical translation and application of basic electrophysiological research findings on arrhythmia mechanisms and therapies.
- Published
- 2021
38. Genome-wide association analyses identify novel Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility
- Author
-
Barc, Julien, Tadros, Rafik, Glinge, Charlotte, Chiang, David Y., Jouni, Mariam, Simonet, Floriane, Jurgens, Sean J., Baudic, Manon, Nicastro, Michele, Potet, Franck, Offerhaus, Joost A., Walsh, Roddy, Choi, Seung Hoan, Verkerk, Arie O., Mizusawa, Yuka, Anys, Soraya, Minois, Damien, Arnaud, Marine, Duchateau, Josselin, Wijeyeratne, Yanushi D., Muir, Alison, Papadakis, Michael, Castelletti, Silvia, Torchio, Margherita, Ortuño, Cristina Gil, Lacunza, Javier, Giachino, Daniela F., Cerrato, Natascia, Martins, Raphaël P., Campuzano, Oscar, Van Dooren, Sonia, Thollet, Aurélie, Kyndt, Florence, Mazzanti, Andrea, Clémenty, Nicolas, Bisson, Arnaud, Corveleyn, Anniek, Stallmeyer, Birgit, Dittmann, Sven, Saenen, Johan, Noël, Antoine, Honarbakhsh, Shohreh, Rudic, Boris, Marzak, Halim, Rowe, Matthew K., Federspiel, Claire, Le Page, Sophie, Placide, Leslie, Milhem, Antoine, Barajas-Martinez, Hector, Beckmann, Britt-Maria, Krapels, Ingrid P., Steinfurt, Johannes, Winkel, Bo Gregers, Jabbari, Reza, Shoemaker, Moore B., Boukens, Bas J., Škorić-Milosavljević, Doris, Bikker, Hennie, Manevy, Federico, Lichtner, Peter, Ribasés, Marta, Meitinger, Thomas, Müller-Nurasyid, Martina, Strauch, Konstantin, Peters, Annette, Schulz, Holger, Schwettmann, Lars, Leidl, Reiner, Heier, Margit, Veldink, Jan H., van den Berg, Leonard H., Van Damme, Philip, Cusi, Daniele, Lanzani, Chiara, Rigade, Sidwell, Charpentier, Eric, Baron, Estelle, Bonnaud, Stéphanie, Lecointe, Simon, Donnart, Audrey, Le Marec, Hervé, Chatel, Stéphanie, Karakachoff, Matilde, Bézieau, Stéphane, London, Barry, Tfelt-Hansen, Jacob, Roden, Dan, Odening, Katja E., Cerrone, Marina, Chinitz, Larry A., Volders, Paul G., van de Berg, Maarten P., Laurent, Gabriel, Faivre, Laurence, Antzelevitch, Charles, Kääb, Stefan, Arnaout, Alain Al, Dupuis, Jean-Marc, Pasquie, Jean-Luc, Billon, Olivier, Roberts, Jason D., Jesel, Laurence, Borggrefe, Martin, Lambiase, Pier D., Mansourati, Jacques, Loeys, Bart, Leenhardt, Antoine, Guicheney, Pascale, Maury, Philippe, Schulze-Bahr, Eric, Robyns, Tomas, Breckpot, Jeroen, Babuty, Dominique, Priori, Silvia G., Napolitano, Carlo, Defaye, Pascal, Anselme, Frédéric, Darmon, Jean Philippe, Wiart, François, de Asmundis, Carlo, Brugada, Pedro, Brugada, Ramon, Arbelo, Elena, Brugada, Josep, Mabo, Philippe, Behar, Nathalie, Giustetto, Carla, Molina, Maria Sabater, Gimeno, Juan R., Hasdemir, Can, Schwartz, Peter J., Crotti, Lia, McKeown, Pascal P., Sharma, Sanjay, Behr, Elijah R., Haissaguerre, Michel, Sacher, Frédéric, Rooryck, Caroline, Tan, Hanno L., Remme, Carol A., Postema, Pieter G., Delmar, Mario, Ellinor, Patrick T., Lubitz, Steven A., Gourraud, Jean-Baptiste, Tanck, Michael W., George, Alfred L., MacRae, Calum A., Burridge, Paul W., Dina, Christian, Probst, Vincent, Wilde, Arthur A., Schott, Jean-Jacques, Redon, Richard, Bezzina, Connie R., KORA-Study Group, Nantes Referral Ctr Inherited Card, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Santé - François Bonamy, Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche en Santé de l'Université de Nantes (IRS-UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) (U1211 INSERM/MRGM), Université de Bordeaux (UB)-Groupe hospitalier Pellegrin-Institut National de la Santé et de la Recherche Médicale (INSERM), Amsterdam UMC - Amsterdam University Medical Center, The MINE study (J.H.V.) has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 772376—EScORIAL). The collaboration project is cofunded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to stimulate public–private partnerships. This study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113, 085475 and 090355. The KORA research platform (KORA, Cooperative Research in the Region of Augsburg) was initiated and financed by the Helmholtz Zentrum München—German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. J. Barc is supported by the research program Etoiles montantes des Pays de la Loire REGIOCARD RPH081-U1087-REG-PDL, ANR JCJC LEARN (R21006NN, RPV21014NNA) and by the H2020-MSCA-IF-2014 Program of the European Commission (RISTRAD-661617). R.T. is supported by the Canadian Heart Rhythm Society’s George Mines Award, the European Society of Cardiology research award, and the Philippa and Marvin Carsley Cardiology Chair. D.Y.C. is supported by Fondation Leducq and National Institutes of Health (NIH) NHGRI T32 (no. 1T32HG010464-01). M. Baudic was supported by IRP—VERACITIES—New Mechanisms for VEntricular ARrhythmia And CardIomeTabolic DIseasES, an I-SITE NExT health and engineering initiative (Ecole Centrale and Nantes University) and by the IRP—GAINES—Genetic Architecture IN cardiovascular disEaSes funded by INSERM and CNRS. R.W. is supported by an Amsterdam Cardiovascular Sciences fellowship. S.C. is supported by the NHLBI BioData Catalyst Fellows Program. C.A.R. is supported by Fondation Leducq, the Dutch Heart Foundation (CVON PREDICT2) and the Innovational Research Incentives Scheme Vidi grant from the Netherlands Organisation for Health Research and Development (ZonMw, 91714371). Y.D.W. is supported by the Robert Lancaster Memorial Fund. M.P. is supported by Cardiac Risk in the Young. S.V.D. is supported by Wetenschappelijk Fonds Willy Gepts VUB-UZ Brussel, project ‘Unravelling the molecular genetic pathways of Brugada Syndrome by cardiomics research’, VUB IRP project ‘IMAGica: an Integrative personalized Medical Approach for Genetic diseases, Inherited Cardia Arrhythmias as a model’ and Innoviris BRIDGE 2017, project ‘IGenCare: Integrated Personalised Medical Genomics Care Solution for Patients with Rare Genetic Diseases’. S.H. is supported by the Barts BRC. B.R. is supported by the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research). B.G.W. is supported by the Danish Heart Foundation. M.B.S. is supported by K23HL127704. Project MinE Belgium was supported by a grant from IWT (no. 140935), the ALS Liga België, the National Lottery of Belgium and the KU Leuven Opening the Future Fund. D.C. and C.L. are supported by HYPERGENES (HEALTH-F4-2007). D.R. is supported by R01 HL149826, P50 GM115305. P.J.S. acknowledges the support of Leducq Foundation for Cardiovascular Research grant 18CVD05. P.V.D. is supported by the Netherlands CardioVascular Research Initiative (CVON PREDICT2). C.A. is supported by NIH HL47678 and HL138103, W.W. Smith Charitable Trust and Wistar Morris Fund. M.B. is Supported by the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research). P.D.L. is supported by UCL/UCLH Biomedicine NIHR and Barts BRC. B.L. is supported by GOA—Antigone 33933. J.B. is supported by a Senior Clinical Fellowship of the Flemish Science Foundation (FWO). E.B. is supported by the British Heart Foundation including BHF Clinical Research Training Fellowship (FS/11/71/28918: Future diagnostic role and new genetic loci in SADS), Cardiac Risk in the Young and Robert Lancaster Memorial fund sponsored by McColl’s Ltd. Retail Group. H.L.T. is supported by the European Union’s Horizon 2020 research and innovation program under acronym ESCAPE-NET, registered under grant agreement no. 733381, and the Dutch Heart Foundation (CVON RESCUED and PREDICT2 projects). M.D. is supported by NIH-RO1 HL134328. P.T.E. was supported by the Fondation Leducq (14CVD01), the NIH (1RO1HL092577, R01HL128914, K24HL105780), the American Heart Association (18SFRN34110082) and by a research grant from Bayer AG to the Broad Institute. S.A.L. is supported by NIH grant 1R01HL139731 and American Heart Association 18SFRN34250007. J.-B.G. received a grant from the Fédération Française de Cardiologie (PREVENT project). A.L.G. is supported by the Fondation Leducq. C.A.M.R. is supported by the Leducq Foundation and Burroughs Wellecome Fund. A.A.W. is supported by the Dutch Heart Foundation (CVON PREDICT2 project). J.-J.S. is supported by the Fondation pour la Recherche Médicale (DEQ20140329545). R.R. and P.G. are supported by the National Agency for Research (ANR-GENSUD-14-CE10-0001). C.R.B. is supported by the Dutch Heart Foundation (CVON PREDICT2 project), the Netherlands Organization for Scientific Research (VICI fellowship, 016.150.610) and Fondation Leducq (17CVD02)., Barc, J, Tadros, R, Glinge, C, Chiang, D, Jouni, M, Simonet, F, Jurgens, S, Baudic, M, Nicastro, M, Potet, F, Offerhaus, J, Walsh, R, Hoan Choi, S, Verkerk, A, Mizusawa, Y, Anys, S, Minois, D, Arnaud, M, Duchateau, J, Wijeyeratne, Y, Muir, A, Papadakis, M, Castelletti, S, Torchio, M, Gil Ortuño, C, Lacunza, J, Giachino, D, Cerrato, N, Martins, R, Campuzano, O, Van Dooren, S, Thollet, A, Kyndt, F, Mazzanti, A, Clémenty, N, Bisson, A, Corveleyn, A, Stallmeyer, B, Dittmann, S, Saenen, J, Noël, A, Honarbakhsh, S, Rudic, B, Marzak, H, Rowe, M, Federspiel, C, Le Page, S, Placide, L, Milhem, A, Barajas-Martinez, H, Beckmann, B, Krapels, I, Steinfurt, J, Gregers Winkel, B, Jabbari, R, Shoemaker, M, Boukens, B, Škorić-Milosavljević, D, Bikker, H, Manevy, F, Lichtner, P, Ribasés, M, Meitinger, T, Müller-Nurasyid, M, Group, K, Veldink, J, van den Berg, L, Van Damme, P, Cusi, D, Lanzani, C, Rigade, S, Charpentier, E, Baron, E, Bonnaud, S, Lecointe, S, Donnart, A, Le Marec, H, Chatel, S, Karakachoff, M, Bézieau, S, London, B, Tfelt-Hansen, J, Roden, D, Odening, K, Cerrone, M, Chinitz, L, Volders, P, van de Berg, M, Laurent, G, Faivre, L, Antzelevitch, C, Kääb, S, Al Arnaout, A, Dupuis, J, Pasquie, J, Billon, O, Roberts, J, Jesel, L, Borggrefe, M, Lambiase, P, Mansourati, J, Loeys, B, Leenhardt, A, Guicheney, P, Maury, P, Schulze-Bahr, E, Robyns, T, Breckpot, J, Babuty, D, Priori, S, Napolitano, C, Referral Center for inherited cardiac arrhythmia, N, de Asmundis, C, Brugada, P, Brugada, R, Arbelo, E, Brugada, J, Mabo, P, Behar, N, Giustetto, C, Sabater Molina, M, Gimeno, J, Hasdemir, C, Schwartz, P, Crotti, L, Mckeown, P, Sharma, S, Behr, E, Haissaguerre, M, Sacher, F, Rooryck, C, Tan, H, Remme, C, Postema, P, Delmar, M, Ellinor, P, Lubitz, S, Gourraud, J, Tanck, M, L. George Jr., A, Macrae, C, Burridge, P, Dina, C, Probst, V, Wilde, A, Schott, J, Redon &, R, Bezzina, C, Cardiology, Graduate School, Medical Biology, ACS - Amsterdam Cardiovascular Sciences, ACS - Heart failure & arrhythmias, Human Genetics, ACS - Pulmonary hypertension & thrombosis, ARD - Amsterdam Reproduction and Development, APH - Methodology, Epidemiology and Data Science, MUMC+: DA KG Polikliniek (9), RS: Carim - H02 Cardiomyopathy, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: Carim - H04 Arrhythmogenesis and cardiogenetics, and Cardiovascular Centre (CVC)
- Subjects
EXPRESSION ,[SDV]Life Sciences [q-bio] ,DIAGNOSIS ,GUIDELINES ,ANNOTATION ,Article ,NAV1.5 Voltage-Gated Sodium Channel ,Young Adult ,MANAGEMENT ,Genetics ,GWAS ,Humans ,Genetic Predisposition to Disease ,610 Medicine & health ,SCN5A ,Alleles ,Brugada Syndrome ,Allele ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,HERITABILITY ,Microtubule-Associated Protein ,Brugada Syndrome, GWAS, SNPs ,COMMON VARIANTS ,Mutation ,Disease Susceptibility ,Human medicine ,ENRICHMENT ,Microtubule-Associated Proteins ,SNPs ,Human ,GENERATION ,Genome-Wide Association Study - Abstract
Brugada syndrome (BrS) is a cardiac arrhythmia disorder associated with sudden death in young adults. With the exception of SCN5A, encoding the cardiac sodium channel Na(V)1.5, susceptibility genes remain largely unknown. Here we performed a genome-wide association meta-analysis comprising 2,820 unrelated cases with BrS and 10,001 controls, and identified 21 association signals at 12 loci (10 new). Single nucleotide polymorphism (SNP)-heritability estimates indicate a strong polygenic influence. Polygenic risk score analyses based on the 21 susceptibility variants demonstrate varying cumulative contribution of common risk alleles among different patient subgroups, as well as genetic associations with cardiac electrical traits and disorders in the general population. The predominance of cardiac transcription factor loci indicates that transcriptional regulation is a key feature of BrS pathogenesis. Furthermore, functional studies conducted on MAPRE2, encoding the microtubule plus-end binding protein EB2, point to microtubule-related trafficking effects on Na(V)1.5 expression as a new underlying molecular mechanism. Taken together, these findings broaden our understanding of the genetic architecture of BrS and provide new insights into its molecular underpinnings. Genome-wide association analyses identify new susceptibility loci for Brugada syndrome. Functional studies implicate microtubule-related trafficking effects on sodium channel expression as an underlying molecular mechanism., European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program [772376-EScORIAL]; Health~Holland; Top Sector Life Sciences Health; Wellcome Trust [076113, 085475, 090355]; Helmholtz Zentrum Munchen-German Research Center for Environmental Health - German Federal Ministry of Education and Research; State of Bavaria; Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universitat, as part of LMUinnovativ; research program Etoiles montantes des Pays de la Loire [REGIOCARD RPH081-U1087-REG-PDL]; ANR JCJC LEARN [R21006NN, RPV21014NNA]; H2020-MSCA-IF-2014 Program of the European Commission [RISTRAD-661617]; Canadian Heart Rhythm Society's George Mines Award; European Society of Cardiology research award; Philippa and Marvin Carsley Cardiology Chair; Fondation Leducq; National Institutes of Health (NIH) NHGRI T32 [1T32HG010464-01]; IRP-VERACITIES-New Mechanisms for VEntricular ARrhythmia And CardIomeTabolic DIseasES an I-SITE NExT health and engineering initiative (Ecole Centrale); IRP-VERACITIES-New Mechanisms for VEntricular ARrhythmia And CardIomeTabolic DIseasES an I-SITE NExT health and engineering initiative (Nantes University); IRP-GAINES-Genetic Architecture IN cardiovascular disEaSes - INSERM; CNRS; Amsterdam Cardiovascular Sciences fellowship; NHLBI BioData Catalyst Fellows Program; Dutch Heart Foundation [CVON PREDICT2]; Innovational Research Incentives Scheme Vidi grant from the Netherlands Organisation for Health Research and Development (ZonMw) [91714371]; Robert Lancaster Memorial Fund; Cardiac Risk in the Young; Wetenschappelijk Fonds Willy Gepts VUB-UZ Brussel; VUB IRP project `IMAGica: an Integrative personalized Medical Approach for Genetic diseases, Inherited Cardia Arrhythmias as a model' and Innoviris BRIDGE 2017; project `IGenCare: Integrated Personalised Medical Genomics Care Solution for Patients with Rare Genetic Diseases'; Barts BRC; DZHK (German Centre for Cardiovascular Research); BMBF (German Ministry of Education and Research); Danish Heart Foundation; IWT [140935]; ALS Liga Belgie; National Lottery of Belgium; KU Leuven Opening the Future Fund; HYPERGENES [HEALTH-F4-2007]; Leducq Foundation for Cardiovascular Research grant [18CVD05]; Netherlands CardioVascular Research Initiative [CVON PREDICT2]; NIH [HL47678, HL138103, 1RO1HL092577, R01HL128914, K24HL105780]; W.W. Smith Charitable Trust; Wistar Morris Fund; GOA-Antigone [33933]; Senior Clinical Fellowship of the Flemish Science Foundation (FWO); British Heart Foundation; BHF Clinical Research Training Fellowship [FS/11/71/28918]; Cardiac Risk in the Young and Robert Lancaster Memorial fund - McColl's Ltd. Retail Group; European Union's Horizon 2020 research and innovation program under acronym ESCAPE-NET [733381]; Dutch Heart Foundation; Fondation Leducq [14CVD01, 17CVD02]; American Heart Association [18SFRN34110082, 18SFRN34250007]; Bayer AG; NIH grant [1R01HL139731]; Federation Francaise de Cardiologie (PREVENT project); Leducq Foundation; Burroughs Wellecome Fund; Fondation pour la Recherche Medicale [DEQ20140329545]; National Agency for Research [ANR-GENSUD-14-CE10-0001]; Netherlands Organization for Scientific Research (VICI fellowship) [016.150.610]; [K23HL127704]; [R01 HL149826]; [P50 GM115305]; [NIH-RO1 HL134328], We are greatly indebted to the patients included in the study. We thank V. Cotard, C. Goutsmedt, M.-F. Le Cunff and N. Bourgeais for assistance in patient recruitment and L. Beekman for his technical support. We thank the biological resource centre for biobanking (CHU Nantes, Nantes Universite, Centre de ressources biologiques (BB0033-00040), F-44000 Nantes, France) for applying the following guidelines68. We are most grateful to the Genomics and Bioinformatics Core Facility of Nantes (GenoBiRD, Biogenouest, IFB) for its technical support. This research has been conducted using the UK Biobank resource; we are grateful to UK Biobank participants. The MINE study (J.H.V.) has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement no. 772376-EScORIAL). The collaboration project is cofunded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships. This study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk.Funding for the project was provided by the Wellcome Trust under award 076113, 085475 and 090355. The KORA research platform (KORA, Cooperative Research in the Region of Augsburg) was initiated and financed by the Helmholtz Zentrum Munchen-German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universitat, as part of LMUinnovativ. J. Barc is supported by the research program Etoiles montantes des Pays de la Loire REGIOCARD RPH081-U1087-REG-PDL, ANR JCJC LEARN (R21006NN, RPV21014NNA) and by the H2020-MSCA-IF-2014 Program of the European Commission (RISTRAD-661617). R.T. is supported by the Canadian Heart Rhythm Society's George Mines Award, the European Society of Cardiology research award, and the Philippa and Marvin Carsley Cardiology Chair. D.Y.C. is supported by Fondation Leducq and National Institutes of Health (NIH) NHGRI T32 (no. 1T32HG010464-01). M. Baudic was supported by IRP-VERACITIES-New Mechanisms for VEntricular ARrhythmia And CardIomeTabolic DIseasES, an I-SITE NExT health and engineering initiative (Ecole Centrale and Nantes University) and by the IRP-GAINES-Genetic Architecture IN cardiovascular disEaSes funded by INSERM and CNRS. R.W. is supported by an Amsterdam Cardiovascular Sciences fellowship. S.C. is supported by the NHLBI BioData Catalyst Fellows Program. C.A.R. is supported by Fondation Leducq, the Dutch Heart Foundation (CVON PREDICT2) and the Innovational Research Incentives Scheme Vidi grant from the Netherlands Organisation for Health Research and Development (ZonMw; 91714371). Y.D.W. is supported by the Robert Lancaster Memorial Fund. M.P. is supported by Cardiac Risk in the Young. S.V.D. is supported by Wetenschappelijk Fonds Willy Gepts VUB-UZ Brussel, project `Unravelling the molecular genetic pathways of Brugada Syndrome by cardiomics research', VUB IRP project `IMAGica: an Integrative personalized Medical Approach for Genetic diseases, Inherited Cardia Arrhythmias as a model' and Innoviris BRIDGE 2017, project `IGenCare: Integrated Personalised Medical Genomics Care Solution for Patients with Rare Genetic Diseases'. S.H. is supported by the Barts BRC. B.R.; is supported by the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research). B.G.W. is supported by the Danish Heart Foundation. M.B.S. is supported by K23HL127704. Project MinE Belgium was supported by a grant from IWT (no. 140935), the ALS Liga Belgie, the National Lottery of Belgium and the KU Leuven Opening the Future Fund. D.C. and C.L. are supported by HYPERGENES (HEALTH-F4-2007). D.R. is supported by R01 HL149826, P50 GM115305. P.J.S. acknowledges the support of Leducq Foundation for Cardiovascular Research grant 18CVD05. P.V.D. is supported by the Netherlands CardioVascular Research Initiative (CVON PREDICT2). C.A. is supported by NIH HL47678 and HL138103, W.W. Smith Charitable Trust and Wistar Morris Fund. M.B. is Supported by the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research). P.D.L. is supported by UCL/UCLH Biomedicine NIHR and Barts BRC. B.L. is supported by GOA-Antigone 33933. J.B. is supported by a Senior Clinical Fellowship of the Flemish Science Foundation (FWO). E.B. is supported by the British Heart Foundation including BHF Clinical Research Training Fellowship (FS/11/71/28918: Future diagnostic role and new genetic loci in SADS), Cardiac Risk in the Young and Robert Lancaster Memorial fund sponsored by McColl's Ltd. Retail Group. H.L.T. is supported by the European Union's Horizon 2020 research and innovation program under acronym ESCAPE-NET, registered under grant agreement no. 733381, and the Dutch Heart Foundation (CVON RESCUED and PREDICT2 projects). M.D. is supported by NIH-RO1 HL134328. P.T.E. was supported by the Fondation Leducq (14CVD01), the NIH (1RO1HL092577, R01HL128914, K24HL105780), the American Heart Association (18SFRN34110082) and by a research grant from Bayer AG to the Broad Institute. S.A.L. is supported by NIH grant 1R01HL139731 and American Heart Association 18SFRN34250007. J.-B.G. received a grant from the Federation Francaise de Cardiologie (PREVENT project). A.L.G. is supported by the Fondation Leducq. C.A.M.R. is supported by the Leducq Foundation and Burroughs Wellecome Fund. A.A.W. is supported by the Dutch Heart Foundation (CVON PREDICT2 project). J.-J.S. is supported by the Fondation pour la Recherche Medicale (DEQ20140329545). R.R. and P.G. are supported by the National Agency for Research (ANR-GENSUD-14-CE10-0001). C.R.B. is supported by the Dutch Heart Foundation (CVON PREDICT2 project), the Netherlands Organization for Scientific Research (VICI fellowship, 016.150.610) and Fondation Leducq (17CVD02).
- Published
- 2022
39. Sex-Related Differences in Cardiac Channelopathies: Implications for Clinical Practice
- Author
-
Yael Ben-Haim, Lauren Yee, Stephan Dobner, Laurent Roten, Katja E. Odening, Helge Servatius, Argelia Medeiros-Domingo, Tobias Reichlin, Andrew D. Krahn, Babken Asatryan, Hildegard Tanner, Carol Ann Remme, Elijah R. Behr, Philippe Chevalier, Jonathan R. Skinner, Lia Crotti, Asatryan, B, Yee, L, Ben-Haim, Y, Dobner, S, Servatius, H, Roten, L, Tanner, H, Crotti, L, Skinner, J, Remme, C, Chevalier, P, Medeiros-Domingo, A, Behr, E, Reichlin, T, Odening, K, Krahn, A, Cardiology, ACS - Heart failure & arrhythmias, and APH - Methodology
- Subjects
Male ,medicine.medical_specialty ,cardiac ,Long QT syndrome ,Torsades de pointes ,Sudden cardiac death ,Sex Factors ,death ,Physiology (medical) ,medicine ,Genetic predisposition ,long QT syndrome ,Humans ,sex ,genetics ,Brugada syndrome ,gender identity ,610 Medicine & health ,Intensive care medicine ,Cardiac channelopathy ,sudden ,business.industry ,death, sudden, cardiac ,Sex related ,arrhythmias, cardiac ,medicine.disease ,Clinical Practice ,Cardiovascular Diseases ,Channelopathies ,Female ,genetic ,Cardiology and Cardiovascular Medicine ,business ,arrhythmias - Abstract
Sex-related differences in prevalence, clinical presentation, and outcome of cardiac channelopathies are increasingly recognized, despite their autosomal transmission and hence equal genetic predisposition among sexes. In congenital long-QT syndrome, adult women carry a greater risk for Torsades de pointes and sudden cardiac death than do men. In contrast, Brugada syndrome is observed predominantly in adult men, with a considerably higher risk of arrhythmic sudden cardiac death in adult men than in women. In both conditions, the risk for arrhythmias varies with age. Sex-associated differences appear less evident in other cardiac channelopathies, likely a reflection of their rare(r) occurrence and our limited knowledge. In several cardiac channelopathies, sex-specific predictors of outcome have been identified. Together with genetic and environmental factors, sex hormones contribute to the sex-related disparities in cardiac channelopathies through modulation of the expression and function of cardiac ion channels. Despite these insights, essential knowledge gaps exist in the mechanistic understanding of these differences, warranting further investigation. Precise application of the available knowledge may improve the individualized care of patients with cardiac channelopathies. Promoting the reporting of sex-related phenotype and outcome parameters in clinical and experimental studies and advancing research on cardiac channelopathy animal models should translate into improved patient outcomes. This review provides a critical digest of the current evidence for sex-related differences in cardiac channelopathies and emphasizes their clinical implications and remaining gaps requiring further research.
- Published
- 2021
40. Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls
- Author
-
Charles Antzelevitch, Ahmad S. Amin, Bo Gregers Winkel, Dan M. Roden, Stefan Kääb, Jonathan R. Skinner, Seiko Ohno, Julien Barc, Birgit Stallmeyer, Carla Giustetto, Connie R. Bezzina, Francesco Mazzarotto, Tomas Robyns, Carlo Napolitano, Stellan Mörner, Doris Škorić-Milosavljević, Sven Dittmann, Kenichiro Yamagata, Sonia Van Dooren, Anniek Corveleyn, Carlo de Asmundis, Ramon Brugada, K Usuda, Yuji Tanaka, Sven Zumhagen, Tadashi Nakajima, Johan Saenen, Elijah R. Behr, Hector Barajas-Martinez, Stéphane Bézieau, Masao Yoshinaga, Georgia Sarquella-Brugada, Paul G.A. Volders, Juan R. Gimeno, Lia Crotti, Charlotte Glinge, Andrea Mazzanti, Ingrid P.C. Krapels, Nicola Whiffin, Sebastian Clauss, Yoshiaki Kaneko, James S. Ware, Minoru Horie, Keiko Shimamoto, Isabelle Denjoy, Pieter G. Postema, Christian Krijger, Takeshi Aiba, Masahiko Kurabayashi, Pyotr G. Platonov, Regina Sebastiano, Cristina Gil Ortuño, Annika Rydberg, Roddy Walsh, Michael J. Ackerman, Hideki Itoh, M. Benjamin Shoemaker, Can Hasdemir, Pascale Guicheney, J. Martijn Bos, Frederic Sacher, Takeru Makiyama, Julieta Lazarte, Maarten P. van den Berg, Dominique Babuty, David J. Tester, Silvia Castelletti, Jacques Mansourati, Antoine Leenhardt, Paul A. van der Zwaag, Sanjay Sharma, Elena Arbelo, Candan Celen, Pier D. Lambiase, Maria Christina Kotta, Johannes Steinfurt, Jean-Baptiste Gourraud, Pedro Brugada, Wataru Shimizu, Josep Brugada, Jørgen K. Kanters, Eline A. Nannenberg, Silvia G. Priori, Mary N. Sheppard, Richard Redon, Morten S. Olesen, Jeroen Breckpot, Britt M. Beckmann, Naomasa Makita, Martin Borggrefe, Rafik Tadros, Jean-Jacques Schott, Jacob Tfelt-Hansen, Steven A. Lubitz, Hatice Şahin, Najim Lahrouchi, Michael Papadakis, Daisuke Hazeki, Kenshi Hayashi, Oscar Campuzano, Katja E. Odening, Federica Dagradi, Eric Schulze-Bahr, Boris Rudic, Hiroki Kimoto, Vincent Probst, Jason D. Roberts, Raphaël P. Martins, Bart Loeys, Daniela F. Giachino, F. Kyndt, Kimie Ohkubo, Taisuke Ishikawa, Catarina Lundin, Lut Van Laer, Patrick T. Ellinor, Maria Sabater Molina, Peter J. Schwartz, Annika Winbo, Wellcome Trust, Rosetrees Trust, British Heart Foundation, Walsh, R, Lahrouchi, N, Tadros, R, Kyndt, F, Glinge, C, Postema, P, Amin, A, Nannenberg, E, Ware, J, Whiffin, N, Mazzarotto, F, Skoric-Milosavljevic, D, Krijger, C, Arbelo, E, Babuty, D, Barajas-Martinez, H, Beckmann, B, Bezieau, S, Bos, J, Breckpot, J, Campuzano, O, Castelletti, S, Celen, C, Clauss, S, Corveleyn, A, Crotti, L, Dagradi, F, de Asmundis, C, Denjoy, I, Dittmann, S, Ellinor, P, Ortuno, C, Giustetto, C, Gourraud, J, Hazeki, D, Horie, M, Ishikawa, T, Itoh, H, Kaneko, Y, Kanters, J, Kimoto, H, Kotta, M, Krapels, I, Kurabayashi, M, Lazarte, J, Leenhardt, A, Loeys, B, Lundin, C, Makiyama, T, Mansourati, J, Martins, R, Mazzanti, A, Morner, S, Napolitano, C, Ohkubo, K, Papadakis, M, Rudic, B, Molina, M, Sacher, F, Sahin, H, Sarquella-Brugada, G, Sebastiano, R, Sharma, S, Sheppard, M, Shimamoto, K, Shoemaker, M, Stallmeyer, B, Steinfurt, J, Tanaka, Y, Tester, D, Usuda, K, van der Zwaag, P, Van Dooren, S, Van Laer, L, Winbo, A, Winkel, B, Yamagata, K, Zumhagen, S, Volders, P, Lubitz, S, Antzelevitch, C, Platonov, P, Odening, K, Roden, D, Roberts, J, Skinner, J, Tfelt-Hansen, J, van den Berg, M, Olesen, M, Lambiase, P, Borggrefe, M, Hayashi, K, Rydberg, A, Nakajima, T, Yoshinaga, M, Saenen, J, Kaab, S, Brugada, P, Robyns, T, Giachino, D, Ackerman, M, Brugada, R, Brugada, J, Gimeno, J, Hasdemir, C, Guicheney, P, Priori, S, Schulze-Bahr, E, Makita, N, Schwartz, P, Shimizu, W, Aiba, T, Schott, J, Redon, R, Ohno, S, Probst, V, Arnaout, A, Amelot, M, Anselme, F, Billon, O, Defaye, P, Dupuis, J, Jesel, L, Laurent, G, Maury, P, Pasquie, J, Wiart, F, Behr, E, Barc, J, Bezzina, C, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), CIC - CHU Bichat, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), CHU Pontchaillou [Rennes], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Ege Üniversitesi, Cardiovascular Centre (CVC), Nantes Referral Ctr Inherited Car, Cardiology, Graduate School, ACS - Heart failure & arrhythmias, Human Genetics, ACS - Amsterdam Cardiovascular Sciences, ACS - Atherosclerosis & ischemic syndromes, MUMC+: DA KG Polikliniek (9), RS: Carim - H02 Cardiomyopathy, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: Carim - H04 Arrhythmogenesis and cardiogenetics, Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Clinical sciences, Heartrhythmmanagement, Medical Genetics, Reproduction and Genetics, and Cardio-vascular diseases
- Subjects
0301 basic medicine ,[SDV]Life Sciences [q-bio] ,Nantes Referral Center for inherited cardiac arrhythmia ,Disease ,Arrhythmias ,030105 genetics & heredity ,ACMG/AMP guidelines ,Brugada ,LQTS ,variant interpretation ,Medicine ,Genetics (clinical) ,Brugada Syndrome ,Brugada syndrome ,Genetics ,Genetics & Heredity ,education.field_of_study ,medicine.diagnostic_test ,Molecular pathology ,3. Good health ,Long QT Syndrome ,Medical genetics ,Population Control ,Cardiology and Cardiovascular Medicine ,Cardiac ,Medical Genetics ,Life Sciences & Biomedicine ,medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,Long QT syndrome ,Population ,610 Medicine & health ,BIO/18 - GENETICA ,Article ,03 medical and health sciences ,Humans ,Genetic Testing ,cardiovascular diseases ,education ,Medicinsk genetik ,Genetic testing ,0604 Genetics ,Science & Technology ,business.industry ,Genetic heterogeneity ,MUTATIONS ,ACMG/AMP guideline ,Arrhythmias, Cardiac ,1103 Clinical Sciences ,MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,medicine.disease ,Mutation ,030104 developmental biology ,Human medicine ,business - Abstract
Purpose: Stringent variant interpretation guidelines can lead to high rates of variants of uncertain significance (VUS) for genetically heterogeneous disease like long QT syndrome (LQTS) and Brugada syndrome (BrS). Quantitative and disease-specific customization of American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) guidelines can address this false negative rate. Methods: We compared rare variant frequencies from 1847 LQTS (KCNQ1/KCNH2/SCN5A) and 3335 BrS (SCN5A) cases from the International LQTS/BrS Genetics Consortia to population-specific gnomAD data and developed disease-specific criteria for ACMG/AMP evidence classes-rarity (PM2/BS1 rules) and case enrichment of individual (PS4) and domain-specific (PM1) variants. Results: Rare SCN5A variant prevalence differed between European (20.8%) and Japanese (8.9%) BrS patients (p = 5.7 x 10(-18)) and diagnosis with spontaneous (28.7%) versus induced (15.8%) Brugada type 1 electrocardiogram (ECG) (p = 1.3 x 10(-13)). Ion channel transmembrane regions and specific N-terminus (KCNH2) and C-terminus (KCNQ1/KCNH2) domains were characterized by high enrichment of case variants and >95% probability of pathogenicity. Applying the customized rules, 17.4% of European BrS and 74.8% of European LQTS cases had (likely) pathogenic variants, compared with estimated diagnostic yields (case excess over gnomAD) of 19.2%/82.1%, reducing VUS prevalence to close to background rare variant frequency. Conclusion: Large case-control data sets enable quantitative implementation of ACMG/AMP guidelines and increased sensitivity for inherited arrhythmia genetic testing., Amsterdam Cardiovascular Sciences fellowship; Dutch Heart Foundation (CVON Predict-2/Concor-genes); Netherlands Organization for Scientific ResearchNetherlands Organization for Scientific Research (NWO) [VICI 016.150.610]; Fondation LeducqLeducq Foundation, R.W. is supported by an Amsterdam Cardiovascular Sciences fellowship. C.R.B. is supported by the Dutch Heart Foundation (CVON Predict-2/Concor-genes), Netherlands Organization for Scientific Research (VICI 016.150.610), and Fondation Leducq. See Supplement for all Acknowledgements.
- Published
- 2020
41. Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome
- Author
-
Yvonne M. Hoedemaekers, M. Ben Shoemaker, Pascale Guicheney, Antoine Leenhardt, Andrea Mazzanti, Minoru Horie, Jan H. Veldink, Isabelle Denjoy, Yu Kucho, Chiea Chuen Khor, Tomas Robyns, Carlo Napolitano, Peter Weeke, J. Martijn Bos, David J. Tester, Hanno L. Tan, Annika Rydberg, Patrick T. Ellinor, Pilar Galan, Taisuke Ishikawa, Seiko Ohno, Peter J. Schwartz, Masao Yoshinaga, Thomas Werge, Marta Ribasés, Bart Loeys, Jean-Jacques Schott, Jacob Tfelt-Hansen, Ulla-Britt Diamant, Marko Ernsting, Georgia Sarquella-Brugada, Yuka Mizusawa, Michael Christiansen, Pyotr G. Platonov, Annika Winbo, Thomas Meitinger, Keiko Shimamoto, Cristina Barlassina, Pieter G. Postema, Takeru Makiyama, Maarten P. van den Berg, Yanushi D. Wijeyeratne, Wataru Shimizu, Charles Antzelevitch, Christopher Newton-Cheh, Martina Müller-Nurasyid, Dan M. Roden, Vincent Probst, Takeshi Aiba, Lia Crotti, Daniele Cusi, Britt M. Beckmann, Johan Saenen, Peter Lichtner, Oscar Campuzano, Tin Aung, Nynke Hofman, Morten S. Olesen, Matteo Pedrazzini, Elijah R. Behr, Karen E. Morrison, Najim Lahrouchi, Katja E. Odening, Andrew D. Krahn, Kari L. Turkowski, J. Peter van Tintelen, Steven A. Lubitz, Federica Dagradi, Josep Brugada, Julien Barc, Birgit Stallmeyer, Stefan Kääb, Sven Zumhagen, Jonathan R. Skinner, Michael W.T. Tanck, Christopher Shaw, Brianna Davies, Eric Schulze-Bahr, Mineo Ozaki, Roddy Walsh, Antoine Andorin, Leonard H. van den Berg, Silvia G. Priori, Johannes Steinfurt, Jean-Baptiste Gourraud, Eline A. Nannenberg, Mark Lathrop, Rafik Tadros, Ramon Brugada, Leander Beekman, Peter M. Andersen, Ryan Pfeiffer, Boris Rudic, Reza Jabbari, Kanae Hasegawa, Jeroen Breckpot, Naomasa Makita, Michael J. Ackerman, Arthur A.M. Wilde, Hideki Itoh, Martin Borggrefe, Elena Arbelo, Connie R. Bezzina, Pamela J. Shaw, Ammar Al-Chalabi, Markus Munter, Cardiology, Graduate School, ACS - Heart failure & arrhythmias, ACS - Amsterdam Cardiovascular Sciences, Human Genetics, Epidemiology and Data Science, APH - Methodology, ACS - Atherosclerosis & ischemic syndromes, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences. Amsterdam University Medical Center, University of Amsterdam, European Reference Network for Rare, Low Prevalence, and Complex Diseases of the Heart (ERN GUARD-Heart), Institut de Cardiologie de Montreal, Université de Montréal (UdeM), Istituto Auxologico Italiano, Shiga University of Medical Science, University of Fukui [Bunkyo], Equipe 3: EREN- Equipe de Recherche en Epidémiologie Nutritionnelle (CRESS - U1153), Université Sorbonne Paris Nord-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CIC - CHU Bichat, Institut National de la Santé et de la Recherche Médicale (INSERM), Lahrouchi, N, Tadros, R, Crotti, L, Mizusawa, Y, Postema, P, Beekman, L, Walsh, R, Hasegawa, K, Barc, J, Ernsting, M, Turkowski, K, Mazzanti, A, Beckmann, B, Shimamoto, K, Diamant, U, Wijeyeratne, Y, Kucho, Y, Robyns, T, Ishikawa, T, Arbelo, E, Christiansen, M, Winbo, A, Jabbari, R, Lubitz, S, Steinfurt, J, Rudic, B, Loeys, B, Shoemaker, M, Weeke, P, Pfeiffer, R, Davies, B, Andorin, A, Hofman, N, Dagradi, F, Pedrazzini, M, Tester, D, Bos, J, Sarquella-Brugada, G, Campuzano, Ó, Platonov, P, Stallmeyer, B, Zumhagen, S, Nannenberg, E, Veldink, J, van den Berg, L, Al-Chalabi, A, Shaw, C, Shaw, P, Morrison, K, Andersen, P, Müller-Nurasyid, M, Cusi, D, Barlassina, C, Galan, P, Lathrop, M, Munter, M, Werge, T, Ribasés, M, Aung, T, Khor, C, Ozaki, M, Lichtner, P, Meitinger, T, van Tintelen, J, Hoedemaekers, Y, Denjoy, I, Leenhardt, A, Napolitano, C, Shimizu, W, Schott, J, Gourraud, J, Makiyama, T, Ohno, S, Itoh, H, Krahn, A, Antzelevitch, C, Roden, D, Saenen, J, Borggrefe, M, Odening, K, Ellinor, P, Tfelt-Hansen, J, Skinner, J, van den Berg, M, Olesen, M, Brugada, J, Brugada, R, Makita, N, Breckpot, J, Yoshinaga, M, Behr, E, Rydberg, A, Aiba, T, Kääb, S, Priori, S, Guicheney, P, Tan, H, Newton-Cheh, C, Ackerman, M, Schwartz, P, Schulze-Bahr, E, Probst, V, Horie, M, Wilde, A, Tanck, M, Bezzina, C, and Cardiovascular Centre (CVC)
- Subjects
Multifactorial Inheritance ,[SDV]Life Sciences [q-bio] ,Genome-wide association study ,030204 cardiovascular system & hematology ,Severity of Illness Index ,Sudden cardiac death ,Electrocardiography ,0302 clinical medicine ,inheritance pattern ,Medicine ,Cardiac and Cardiovascular Systems ,Age of Onset ,Genetics ,0303 health sciences ,Kardiologi ,Genetic disorder ,genome-wide association study ,Prognosis ,3. Good health ,Phenotype ,Medical genetics ,Cardiology and Cardiovascular Medicine ,Adult ,medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,Adolescent ,Genotype ,Long QT syndrome ,610 Medicine & health ,BIO/18 - GENETICA ,QT interval ,Polymorphism, Single Nucleotide ,03 medical and health sciences ,Young Adult ,Physiology (medical) ,long QT syndrome ,Humans ,Genetic Predisposition to Disease ,cardiovascular diseases ,Alleles ,Genetic Association Studies ,MED/01 - STATISTICA MEDICA ,030304 developmental biology ,Neurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7] ,business.industry ,inheritance patterns ,MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,Heritability ,medicine.disease ,Genetic architecture ,Genome-wide Association Study ,Inheritance Patterns ,Long Qt Syndrome ,Case-Control Studies ,Human medicine ,business - Abstract
Background: Long QT syndrome (LQTS) is a rare genetic disorder and a major preventable cause of sudden cardiac death in the young. A causal rare genetic variant with large effect size is identified in up to 80% of probands (genotype positive) and cascade family screening shows incomplete penetrance of genetic variants. Furthermore, a proportion of cases meeting diagnostic criteria for LQTS remain genetically elusive despite genetic testing of established genes (genotype negative). These observations raise the possibility that common genetic variants with small effect size contribute to the clinical picture of LQTS. This study aimed to characterize and quantify the contribution of common genetic variation to LQTS disease susceptibility. Methods: We conducted genome-wide association studies followed by transethnic meta-analysis in 1656 unrelated patients with LQTS of European or Japanese ancestry and 9890 controls to identify susceptibility single nucleotide polymorphisms. We estimated the common variant heritability of LQTS and tested the genetic correlation between LQTS susceptibility and other cardiac traits. Furthermore, we tested the aggregate effect of the 68 single nucleotide polymorphisms previously associated with the QT-interval in the general population using a polygenic risk score. Results: Genome-wide association analysis identified 3 loci associated with LQTS at genome-wide statistical significance ( P −8 ) near NOS1AP , KCNQ1 , and KLF12 , and 1 missense variant in KCNE1 (p.Asp85Asn) at the suggestive threshold ( P −6 ). Heritability analyses showed that ≈15% of variance in overall LQTS susceptibility was attributable to common genetic variation ( h2SNP 0.148; standard error 0.019). LQTS susceptibility showed a strong genome-wide genetic correlation with the QT-interval in the general population (r g =0.40; P =3.2×10 −3 ). The polygenic risk score comprising common variants previously associated with the QT-interval in the general population was greater in LQTS cases compared with controls ( P P Conclusions: This work establishes an important role for common genetic variation in susceptibility to LQTS. We demonstrate overlap between genetic control of the QT-interval in the general population and genetic factors contributing to LQTS susceptibility. Using polygenic risk score analyses aggregating common genetic variants that modulate the QT-interval in the general population, we provide evidence for a polygenic architecture in genotype negative LQTS.
- Published
- 2020
42. Heritable arrhythmias associated with abnormal function of cardiac potassium channels
- Author
-
Lia Crotti, Michael C. Sanguinetti, Katja E. Odening, Crotti, L, Odening, K, and Sanguinetti, M
- Subjects
Heredity ,Potassium Channels ,Physiology ,Long QT syndrome ,Short QT syndrome ,Action Potentials ,610 Medicine & health ,Biology ,medicine.disease_cause ,Risk Assessment ,Sudden cardiac death ,Basal (phylogenetics) ,Heart Rate ,Risk Factors ,Physiology (medical) ,Atrial Fibrillation ,medicine ,Animals ,Humans ,Genetic Predisposition to Disease ,Myocytes, Cardiac ,Potassium channel ,Membrane potential ,Mutation ,Cardiac arrhythmia ,Arrhythmias, Cardiac ,MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,medicine.disease ,Prognosis ,Long QT Syndrome ,Phenotype ,Potassium ,Cardiology and Cardiovascular Medicine ,Neuroscience ,Anti-Arrhythmia Agents - Abstract
Cardiomyocytes express a surprisingly large number of potassium channel types. The primary physiological functions of the currents conducted by these channels are to maintain the resting membrane potential and mediate action potential repolarization under basal conditions and in response to changes in the concentrations of intracellular sodium, calcium, and ATP/ADP. Here, we review the diversity and functional roles of cardiac potassium channels under normal conditions and how heritable mutations in the genes encoding these channels can lead to distinct arrhythmias. We briefly review atrial fibrillation and J-wave syndromes. For long and short QT syndromes, we describe their genetic basis, clinical manifestation, risk stratification, traditional and novel therapeutic approaches, as well as insights into disease mechanisms provided by animal and cellular models.
- Published
- 2019
43. Untersuchungen zum Auftreten von Myxosporidien bei Nutz- und Wildfischarten aus Binnengewässern der DDR
- Author
-
Sedlaczek, Jürgen, Odening, K., Hiepe, T., Reimer, L. W., and Böhme, R.
- Subjects
inland waters ,Myxidium spp ,spores ,Sporen ,fish disease ,32 Biologie ,season dynamics ,developmental stages ,parasites ,Chloromyxum spp ,Süßwasserfischarten ,Myxobilatus spp ,taxonomy ,fish health ,determination ,ddc:570 ,Myxobolus spp ,570 Biowissenschaften, Biologie ,Thelohanellus spp ,Deutschland (DDR) ,Henneguya spp ,Myxosporeans ,Germany (GDR) ,Saisondynamik ,species of freshwater fish ,Parasiten ,Taxonomie ,Binnengewässer ,Zschokkella spp ,infection ,Sphaerospora spp ,Infektion ,Myxosporidien ,Fischgesundheit ,Entwicklungsstadien ,Fischkrankheit ,Morphologie ,morphological description - Abstract
Die Arbeit verfolgt das Ziel, eine Übersicht über die bei verschiedenen Süßwasserfischarten festgestellten Myxosporidien zu geben. Aus Gewässern der DDR-Bezirke Potsdam, Berlin, Frankfurt (Oder), Cottbus und Dresden wurden 1.850 Fische (1.015 Karpfen, 258 Regenbogenforellen, 143 Silberkarpfen, 104 Plötzen sowie weitere 22 Fischarten in geringer Zahl untersucht. Es wurden 40 Myxosporidienarten folgender taxonomischer Gruppen nachgewiesen: Myxidiidae (7), Sphaerosporidae (6), Chloromyxidae (4) und Myxobolidae (23). In der Arbeit sind Maße, Fotos und Zeichnungen der Parasiten enthalten. Es wurden Angaben über die Taxonomie, Organspezifität, Saisondynamik, Epizootiologie und Auswirkungen auf die Fischgesundheit gemacht. Es erfolgte ein Vergleich mit früheren Arbeiten in der DDR auf diesem Gebiet. Der Artenbestand an Myxosporidien konnte um 39 Arten erweitert werden. Anhand faunistischer Arbeiten aus benachbarten Ländern wurden die Bedeutung und Perspektiven zum Auftreten von Myxosporidiosen in der DDR herausgestellt. This work aims to give an overview about the detected Myxosporeans in different species of freshwater fishes. From inland waters of the GDR districts Potsdam, Berlin, Frankfurt (Oder), Cottbus and Dresden 1.850 fishes (1.015 carps, 258 rainbow trouts, 143 silver carps, 104 roach and more 22 Fish species in small numbers were studied. 40 Myxosporean species of following taxonomic groups were detected: Myxidiidae (7), Sphaerosporidae (6), Chloromyxidae (4) und Myxobolidae (23). In this work are presented dimensions, photos and drawings of the parasites. Details are given on taxonomy, organ specificity, season dynamics, epizootiology and the impact on fish health A comparison with previous work in the GDR on this subject was carried out. The species inventory on Myxosporidia could be extended to 39 species. Based on faunal work from neighboring countries the importance and prospects for occurrence of Myxosporidiosis in the GDR were highlighted.
- Published
- 2016
44. Familial dilated cardiomyopathy associated with a novel heterozygous RYR2 early truncating variant.
- Author
-
Costa S, Medeiros-Domingo A, Gasperetti A, Breitenstein A, Steffel J, Guidetti F, Flammer A, Odening K, Ruschitzka F, Duru F, and Saguner AM
- Subjects
- Connectin genetics, Heterozygote, Humans, Pedigree, Ryanodine Receptor Calcium Release Channel, Cardiomyopathy, Dilated
- Published
- 2021
- Full Text
- View/download PDF
45. [QT Interval and Its Prolongation - What Does It Mean?]
- Author
-
Castiglione A and Odening K
- Subjects
- Arrhythmias, Cardiac, Death, Sudden, Cardiac, Female, Heart Rate physiology, Humans, Male, Syncope physiopathology, Electrocardiography classification, Electrocardiography methods, Long QT Syndrome diagnosis, Long QT Syndrome physiopathology
- Abstract
The assessment of the QT interval has been an integral part of ECG interpretation since the first descriptions of long QT syndrome by Wolff in 1950 and by Jervell and Lange-Nielsen in 1957. The correct measurement of the QT interval as well as a correct interpretation of the causes and of the clinical consequences of a QT prolongation, however, may be difficult even for trained internists and cardiologists. In this review, we give an overview on physiological determinants of cardiac repolarization, its marker in the surface ECG - the QT interval -, methods to correctly assess QT interval duration, causes for pathologically prolonged QT intervals, and resulting clinical consequences. A correct measurement of the QT interval should be performed by using the "tangent method", excluding possible U waves. A heart rate correction formula should be employed to determine the heart rate corrected QT interval (QTc).Many factors, which may prolong the QT interval, should be checked whenever a QTc prolongation is observed. These include drugs, electrolyte imbalances, hormonal influence, and comorbidities. The correct management of a patient with (genetically determined) LQTS starts with a risk stratification based on genotype, ECG phenotype, clinical history, age, sex, concomitant diseases, drug therapies, and family history for syncope or sudden cardiac death. The therapeutic approaches for LQTS are multimodal. Prevention is the basis of the therapy and includes avoiding known risk factors / and potentially QT-prolonging drugs, and a pharmacological treatment with non-selective beta blockers. According to the risk profile and to the patient's lifestyle the implantation of an ICD or a pacemaker should be considered., Competing Interests: Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht., (© Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2020
- Full Text
- View/download PDF
46. Long-term follow-up of implantable cardioverter-defibrillators in Short QT syndrome.
- Author
-
El-Battrawy I, Besler J, Ansari U, Liebe V, Schimpf R, Tülümen E, Rudic B, Lang S, Odening K, Cyganek L, Wolpert C, Zhou X, Borggrefe M, and Akin I
- Subjects
- Arrhythmias, Cardiac physiopathology, Follow-Up Studies, Humans, Time Factors, Treatment Outcome, Arrhythmias, Cardiac therapy, Defibrillators, Implantable, Electrocardiography
- Abstract
Background: Short QT syndrome (SQTS) is associated with sudden cardiac death and implantable cardioverter-defibrillator (ICD) implantation is recommended in this rare disease. However, only a few SQTS families have been reported in literature with limited follow-up data., Objectives: In the recent study, we describe the outcome data of 57 SQTS patients receiving ICD implantation. This includes seven SQTS families consecutively admitted to our hospital between 2002 and 2017 as well as patients reported in published literature., Methods: Seven SQTS patients admitted to our hospital were followed up. Additionally, 7 studies out of a total of 626 researched articles were identified through systematic database search (PubMed, Web of Science, Cochrane Library, and Cinahl) and their data analyzed according to our model., Results: Complications during a median follow-up time of 67.4 months (IQR 6-162 months) were documented in 31 (54%) patients. Inappropriate shocks were seen in 33% due to T wave oversensing (8.7%), supraventricular tachycardia (19%), lead failure and fracture (21%). Further complications were infection (10%), battery depletion (7%) and psychological distress (3.5%). Appropriate shocks were documented in 19%. Three patients (5%) were treated with s-ICD due to recurrent complications of transvenous ICD., Conclusion: ICD therapy is an effective therapy in SQTS patients. However, it is also associated with significant risk of device-related complications.
- Published
- 2019
- Full Text
- View/download PDF
47. The potential impact of new generation transgenic methods on creating rabbit models of cardiac diseases.
- Author
-
Bősze Z, Major P, Baczkó I, Odening KE, Bodrogi L, Hiripi L, and Varró A
- Subjects
- Animals, Animals, Genetically Modified, DNA Transposable Elements genetics, Disease Models, Animal, Genomics, Humans, Rabbits, Gene Transfer Techniques, Heart Diseases
- Abstract
Since the creation of the first transgenic rabbit thirty years ago, pronuclear microinjection remained the single applied method and resulted in numerous important rabbit models of human diseases, including cardiac deficiencies, albeit with low efficiency. For additive transgenesis a novel transposon mediated method, e.g., the Sleeping Beauty transgenesis, increased the efficiency, and its application to create cardiac disease models is expected in the near future. The targeted genome engineering nuclease family, e.g., the zink finger nuclease (ZFN), the transcription activator-like effector nuclease (TALEN) and the newest, clustered regularly interspaced short palindromic repeats (CRISPR) with the CRISPR associated effector protein (CAS), revolutionized the non-mouse transgenesis. The latest gene-targeting technology, the CRISPR/CAS system, was proven to be efficient in rabbit to create multi-gene knockout models. In the future, the number of tailor-made rabbit models produced with one of the above mentioned methods is expected to exponentially increase and to provide adequate models of heart diseases., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
48. Transgenic rabbit models to investigate the cardiac ion channel disease long QT syndrome.
- Author
-
Lang CN, Koren G, and Odening KE
- Subjects
- Animals, Animals, Genetically Modified, Humans, Long QT Syndrome drug therapy, Long QT Syndrome metabolism, Long QT Syndrome physiopathology, Rabbits, Disease Models, Animal, Ion Channels metabolism, Long QT Syndrome genetics
- Abstract
Long QT syndrome (LQTS) is a rare inherited channelopathy caused mainly by different mutations in genes encoding for cardiac K(+) or Na(+) channels, but can also be caused by commonly used ion-channel-blocking and QT-prolonging drugs, thus affecting a much larger population. To develop novel diagnostic and therapeutic strategies to improve the clinical management of these patients, a thorough understanding of the pathophysiological mechanisms of arrhythmogenesis and potential pharmacological targets is needed. Drug-induced and genetic animal models of various species have been generated and have been instrumental for identifying pro-arrhythmic triggers and important characteristics of the arrhythmogenic substrate in LQTS. However, due to species differences in features of cardiac electrical function, these different models do not entirely recapitulate all aspects of the human disease. In this review, we summarize advantages and shortcomings of different drug-induced and genetically mediated LQTS animal models - focusing on mouse and rabbit models since these represent the most commonly used small animal models for LQTS that can be subjected to genetic manipulation. In particular, we highlight the different aspects of arrhythmogenic mechanisms, pro-arrhythmic triggering factors, anti-arrhythmic agents, and electro-mechanical dysfunction investigated in transgenic LQTS rabbit models and their translational application for the clinical management of LQTS patients in detail. Transgenic LQTS rabbits have been instrumental to increase our understanding of the role of spatial and temporal dispersion of repolarization to provide an arrhythmogenic substrate, genotype-differences in the mechanisms for early afterdepolarization formation and arrhythmia maintenance, mechanisms of hormonal modification of arrhythmogenesis and regional heterogeneities in electro-mechanical dysfunction in LQTS., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
49. Electro-mechanical dysfunction in long QT syndrome: Role for arrhythmogenic risk prediction and modulation by sex and sex hormones.
- Author
-
Lang CN, Menza M, Jochem S, Franke G, Perez Feliz S, Brunner M, Koren G, Zehender M, Bugger H, Jung BA, Foell D, Bode C, and Odening KE
- Subjects
- Action Potentials, Animals, Biomechanical Phenomena, Female, Long QT Syndrome pathology, Male, Rabbits, Risk, Electrophysiological Phenomena, Gonadal Steroid Hormones blood, Long QT Syndrome blood, Long QT Syndrome physiopathology, Mechanical Phenomena, Sex Characteristics
- Abstract
Long QT syndrome (LQTS) is a congenital arrhythmogenic channelopathy characterized by impaired cardiac repolarization. Increasing evidence supports the notion that LQTS is not purely an "electrical" disease but rather an "electro-mechanical" disease with regionally heterogeneously impaired electrical and mechanical cardiac function. In the first part, this article reviews current knowledge on electro-mechanical (dys)function in LQTS, clinical consequences of the observed electro-mechanical dysfunction, and potential underlying mechanisms. Since several novel imaging techniques - Strain Echocardiography (SE) and Magnetic Resonance Tissue Phase Mapping (TPM) - are applied in clinical and experimental settings to assess the (regional) mechanical function, advantages of these non-invasive techniques and their feasibility in the clinical routine are particularly highlighted. The second part provides novel insights into sex differences and sex hormone effects on electro-mechanical cardiac function in a transgenic LQT2 rabbit model. Here we demonstrate that female LQT2 rabbits exhibit a prolonged time to diastolic peak - as marker for contraction duration and early relaxation - compared to males. Chronic estradiol-treatment enhances these differences in time to diastolic peak even more and additionally increases the risk for ventricular arrhythmia. Importantly, time to diastolic peak is particularly prolonged in rabbits exhibiting ventricular arrhythmia - regardless of hormone treatment - contrasting with a lack of differences in QT duration between symptomatic and asymptomatic LQT2 rabbits. This indicates the potential added value of the assessment of mechanical dysfunction in future risk stratification of LQTS patients., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
50. Possible gender-related differences in the risk-to-benefit ratio of thrombolysis for acute submassive pulmonary embolism.
- Author
-
Geibel A, Olschewski M, Zehender M, Wilsch M, Odening K, Heinrich F, Kasper W, and Konstantinides S
- Subjects
- Aged, Anticoagulants administration & dosage, Anticoagulants therapeutic use, Female, Fibrinolytic Agents administration & dosage, Fibrinolytic Agents therapeutic use, Germany epidemiology, Hemorrhage, Heparin administration & dosage, Heparin therapeutic use, Humans, Male, Prospective Studies, Pulmonary Embolism pathology, Registries, Risk Assessment, Severity of Illness Index, Gender Identity, Pulmonary Embolism drug therapy, Pulmonary Embolism mortality, Thrombolytic Therapy
- Abstract
The indications for thrombolytic treatment in normotensive patients with pulmonary embolism (PE) are still the subject of debate, and it also remains questionable whether the efficacy and safety of thrombolysis are similar in men and women. To address the latter issue, the present study analyzed a large population of 428 women and 291 men with acute submassive PE derived from a prospective multicenter registry. Initial treatment consisted either of thrombolysis (<24 hours after diagnosis) or heparin alone. Thirty-day overall mortality was almost identical (11%) in heparin-treated men and women. Early thrombolysis was associated with drastically reduced death rates (2.7% vs 11% in the heparin group, p = 0.033) in men, whereas the reduction was nonsignificant (p = 0.181) in women. Multivariate analysis revealed that early thrombolysis was independently associated with reduced mortality rates in men (odds ratio 0.21, 95% confidence interval 0.05 to 0.96). In comparison, its favorable effect in women was marginal (odds ratio 0.77, 95% confidence interval 0.30 to 1.97). Gender-specific differences were also observed with regard to the reduction of symptomatic PE recurrence (in men, from 21.6% to 8.2%, p = 0.009; in women, from 16.9% to 8.3%, p = 0.049). In contrast, thrombolysis resulted in a more than threefold increase in major bleeding in women (from 8.4% to 27.1%, p <0.001), a more pronounced effect than in men (from 6.9% to 15.1%, p = 0.055). In conclusion, the present study generated the hypothesis that women with submassive PE might benefit less from thrombolytic treatment in terms of survival and PE recurrence and that they could be exposed to a higher bleeding risk compared with men.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.